The developing cancer stem-cell model: Clinical challenges and opportunities

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages

  Vermeulen, Louis ^a   de Sousa e Melo, Felipe ^a   Richel, Dick J ^a   Medema, Jan Paul ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; IMATINIB; NOTCH RECEPTOR; SCATTER FACTOR; WNT PROTEIN;

BCR ABL GENE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL COUNT; CELL DEDIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; DISEASE MARKER; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HUMAN; MULTIPLE MYELOMA; MYOFIBROBLAST; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; STEM CELL NICHE; STEM CELL TRANSPLANTATION; TESTIS CANCER; TREATMENT RESPONSE; TUMOR GENE; TUMOR MICROENVIRONMENT;

CELL DEDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84856501335     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70257-1     Document Type: Note

References (75)

1. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP Cancer stem cells-old concepts, new insights. Cell Death Differ 2008, 15:947-958.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
3. Al Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004, 14:43-47.
4. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
5. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106:13820-13825.
6. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:2428.
7. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
8. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
9. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
11. Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
12. Vermeulen L, De Sousa E Melo F, van der Heijdon M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12:468-476.
13. Fearon ER, Vogelstein B A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
14. Heppner GH Tumor heterogeneity. Cancer Res 1984, 44:2259-2265.
15. Nowell PC The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
16. Weiss L Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 2000, 19:193-383.
17. O'Brien CA, Pollett A, Gallinger S, Dick JE A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
18. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
19. Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008, 14:450-460.
20. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
21. Vermeulen L, Todaro M, de Sousa MF, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008, 105:13427-13432.
22. Zucchi I, Sanzone S, Astigiano S, et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci USA 2007, 104:10476-10481.
23. Borovski T, Vermeulen L, Sprick MR, Medema JP One renegade cancer stem cell?. Cell Cycle 2009, 8:803-808.
24. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
25. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
26. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
27. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
28. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.
29. Adams JM, Strasser A Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res 2008, 68:4018-4021.
30. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
31. Zhu L, Gibson P, Currle DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607.
32. Snippert HJ, van Es JH, van den Born M, et al. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 2009, 136:2187-2194.
33. Medema JP, Vermeulen L Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011, 474:318-326.
34. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010, 5:14062.
35. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010, 102:1636-1644.
36. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010, 70:9937-9948.
37. Teng Y, Wang X, Wang Y, Ma D Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010, 392:373-379.
38. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
39. Varnat F, Siegl-Cachedenier I, Malerba M, Gervaz P, Altaba A Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol Med 2010, 2:440-457.
40. Bjornson CR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999, 283:534-537.
41. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
42. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999, 284:1168-1170.
43. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
44. Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
45. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
46. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
47. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
48. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
49. Roeder I, Horn M, Glauche I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006, 12:1181-1184.
50. Bardsley MR, Horvath VJ, Asuzu DT, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010, 139:942-952.
51. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11:942-949.
52. Heinrich MC Imatinib treatment of metastatic GIST: don't stop (believing). Lancet Oncol 2010, 11:910-911.
53. Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res 2011, 71:5307-5316.
54. Todaro M, Francipane MG, Medema JP, Stassi G Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
55. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
56. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15:4234-4241.
57. Masters JR, Koberle B Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003, 3:517-525.
58. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123:97-108.
59. Tamura K, Aoyagi M, Wakimoto H, et al. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 2010, 113:310-318.
60. Sottoriva A, Verhoeff JJ, Borovski T, et al. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 2010, 70:46-56.
61. Sottoriva A, Vermeulen L, Tavare S Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol 2011, 7:1001132.
62. Huff CA, Matsui W, Smith BD, Jones RJ The paradox of response and survival in cancer therapeutics. Blood 2006, 107:431-434.
63. Borovski T, De Sousa E Melo, Vermeulen L, Medema JP Cancer stem cell niche: the place to be. Cancer Res 2011, 71:634-639.
64. De Sousa E Melo, Vermeulen L, Richel DJ, Medema JP Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2010, 17:647-653.
65. van der Horst EH, Chinn L, Wang M, et al. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia 2009, 11:355-364.
66. Levina V, Marrangoni A, Wang T, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010, 70:338-346.
67. Todaro M, Perez AM, Scopelliti A, Medema JP, Stassi G IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7:309-313.
68. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
69. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
70. Bell JB, Millar BC, Montes-Borinaga A, et al. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone. Hematol Oncol 1990, 8:347-353.
71. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008, 14:8205-8212.
72. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009, 14:1070-1082.
73. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010, 288:99-106.
74. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011, 29:1547-1555.
75. Janikova M, Skarda J, Dziechciarkova M, et al. Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010, 154:321-326.